| TriSalus Life Sciences, Inc. (TLSI) Q1 2025 Earnings Conference Call Transcript |
TriSalus Life Sciences, Inc. (TLSI) Q1 2025 Earnings Conference Call Transcript |
seekingalpha.com |
2025-05-15 22:45:30 |
Czytaj oryginał (ang.) |
| TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates |
TriSalus Life Sciences, Inc. (TLSI) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.54 per share a year ago. |
zacks.com |
2025-05-15 13:11:09 |
Czytaj oryginał (ang.) |
| TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance |
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance. |
businesswire.com |
2025-05-15 11:00:00 |
Czytaj oryginał (ang.) |
| TriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference Call |
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies, announced today that it will host a conference call and webcast on Thursday May 15, 2025 at 8:00 AM eastern time to discuss its financial results for the quarter ended March 31, 2025. A press release detailing the results. |
businesswire.com |
2025-05-12 20:30:00 |
Czytaj oryginał (ang.) |
| TriSalus Life Sciences, Inc. (TLSI) Soars 6.6%: Is Further Upside Left in the Stock? |
TriSalus Life Sciences, Inc. (TLSI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2025-04-09 13:50:54 |
Czytaj oryginał (ang.) |
| TriSalus Life Sciences: Optimistic Guidance For 2025, But There Are Still Risks |
TriSalus Life Sciences aims to achieve positive cash flow by 2025, driven by expanding sales of their TriNav system and reducing operating expenses. The PERIO-03 trial for nelitolimod, a potential treatment for liver-involved cancers, is a key catalyst, with top-line data expected later this year. Financially, TLSI reported a net loss of $30 million for FY 2024, but expects to be EBITDA positive with 50% sales growth in 2025. |
seekingalpha.com |
2025-03-30 12:02:47 |
Czytaj oryginał (ang.) |
| TriSalus Life Sciences, Inc. (TLSI) Q4 2024 Earnings Call Transcript |
TriSalus Life Sciences, Inc. (NASDAQ:TLSI ) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET Company Participants Jeremy Feffer - Managing Director, LifeSci Advisors Mary Szela - President & Chief Executive Officer James Young - Chief Financial Officer Richard Marshall - Medical Director Conference Call Participants Carl Burns - Northland Capital Markets Justin Walsh - JonesTrading Frank Takkinen - Lake Street Capital Markets Suraj Kalia - Oppenheimer & Company William Plovanic - Canaccord Genuity Operator Good morning, and welcome to TriSalus Life Sciences Fourth Quarter and Full Year 2024 Earnings Conference Call. Currently, all participants are in a listen-only mode. |
seekingalpha.com |
2025-03-27 16:02:18 |
Czytaj oryginał (ang.) |
| TriSalus Life Sciences, Inc. (TLSI) Reports Q4 Loss, Tops Revenue Estimates |
TriSalus Life Sciences, Inc. (TLSI) came out with a quarterly loss of $0.35 per share in line with the Zacks Consensus Estimate. This compares to loss of $1.56 per share a year ago. |
zacks.com |
2025-03-27 11:40:25 |
Czytaj oryginał (ang.) |
| TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update |
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences Inc., (Nasdaq: TLSI), oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies, and with our investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications, today announced its financial results for the fourth quarter and full yea. |
businesswire.com |
2025-03-27 09:30:00 |
Czytaj oryginał (ang.) |
| TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav® Infusion System Mapping |
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), which seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, announced today that the Centers for Medicare & Medicaid Services (CMS) has established a new Level II HCPCS code for the TriNav® Infusion System, effective April 1, 2025. This new code, C8004, provides reimb. |
businesswire.com |
2025-03-26 10:00:00 |
Czytaj oryginał (ang.) |
| TriSalus Life Sciences® Announces That Its Researchers Received Two JVIR Top Paper Awards for the Publication of “Intra-arterial Pressure-Enabled Drug Delivery™ Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model” |
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), TriSalus Life Sciences, which seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, announced today that company researchers received two JVIR Top Paper Awards for a recent publication, including the JVIR Editor's Award for Distinguished Laboratory Investigation and the J. |
businesswire.com |
2025-03-06 10:00:00 |
Czytaj oryginał (ang.) |
| TriSalus Life Sciences Announces Key Appointments to Board of Directors |
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI), a biomedical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies and its investigational immunotherapy, today announced the appointment of two distinguished HealthCare Industry veterans to its Board of Directors. Mr. William J. Valle and Gary B. Gordon, M.D., Ph.D., joined the Company's Board of Directors, effective a. |
businesswire.com |
2025-02-03 18:05:00 |
Czytaj oryginał (ang.) |
| TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed |
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI), a biomedical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies and its investigational immunotherapy, today announced that it has requested a drawdown of $10 million under its previously announced $50 million credit agreement with OrbiMed, a healthcare investment firm. Pursuant to the to the Agreement, OrbiMed agree. |
businesswire.com |
2025-02-03 10:00:00 |
Czytaj oryginał (ang.) |
| TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call |
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI), is announcing preliminary unaudited fourth quarter and full year 2024 financial results and details of the upcoming conference call. Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results Full financial results for the year ended December 31, 2024 are in the process of being finalized, however initial and preliminary results show revenue, driven solely by the TriNav® Infusion System, of approximately $8.3 m. |
businesswire.com |
2025-01-23 10:00:00 |
Czytaj oryginał (ang.) |
| TriSalus Life Sciences: Continuing To Maintain Optimism As Costs Are Cut |
TriSalus Life Sciences continues to develop its TriNav infusion system, expanding its reach in liver and pancreatic cancer treatment, despite shifting focus from drug development. TLSI's financials show a $2.4 million net loss for the quarter, but management is optimistic about turning cash flow positive by 2025. The company faces risks with low cash reserves and potential need for dilutive fundraising, despite cost reduction efforts and growing product sales. |
seekingalpha.com |
2024-12-24 13:29:29 |
Czytaj oryginał (ang.) |
| TriSalus Life Sciences, Inc. (TLSI) Q3 2024 Earnings Call Transcript |
TriSalus Life Sciences, Inc. (NASDAQ:TLSI ) Q3 2024 Earnings Conference Call November 14, 2024 9:00 AM ET Company Participants Jim Young - Senior Vice President, Investor Relations & Treasurer Mary Szela - President & Chief Executive Officer Sean Murphy - Chief Financial Officer Conference Call Participants Jason Wittes - ROTH Suraj Kalia - Oppenheimer & Company William Plovanic - Canaccord Genuity Justin Walsh - JonesTrading Operator Good morning, and welcome to TriSalus Science's Third Quarter 2024 Earnings Conference Call. Currently, all participants are in a listen-only mode. |
seekingalpha.com |
2024-11-14 12:22:35 |
Czytaj oryginał (ang.) |
| TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with Liver Cancer |
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients suffering from liver cancer through its advanced delivery technology as well as an investigational immunotherapy, nelitolimod, has announced a strategic partnership with Geo-Med, LLC (“Geo-Med”), a certified Service-Disabled Veteran-Owned Small Business (SDVOSB), to expand availability of the TriNav Infusion System (“TriNav”) to U.S. |
businesswire.com |
2024-11-11 09:00:00 |
Czytaj oryginał (ang.) |
| TriSalus Life Sciences initiated with a Buy at Roth MKM |
Roth MKM analyst Jason Wittes initiated coverage of TriSalus Life Sciences with a Buy rating and $11 price target. The company's TriNav catheter significantly improves drug delivery with pressure enabled drug delivery, which is on its way to becoming the standard of care for delivering therapeutics to tumors in the liver, the analyst tells investors in a research note. The firm says this alone supports 50% growth through 2027, with upside from clinical expansion beyond the liver. |
https://thefly.com |
2024-11-11 07:09:26 |
Czytaj oryginał (ang.) |
| TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call |
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery technology and novel immunotherapy, nelitolimod, announced today it will host a conference call and webcast on November 14, 2024, at 9:00 a.m. ET to discuss financial results for the third quarter ended September 30, 2024, and provide a business update. A press release detailing the third quarter re. |
businesswire.com |
2024-10-31 10:00:00 |
Czytaj oryginał (ang.) |
| TriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit |
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery technology and novel immunotherapy, nelitolimod, announced today that Mary Szela, Chief Executive Officer and President of TriSalus, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Thursday, October 17, 2024. Details for the fireside ch. |
businesswire.com |
2024-10-14 20:05:00 |
Czytaj oryginał (ang.) |
| TriSalus Life Sciences, Inc. (TLSI) Q2 2024 Earnings Call Transcript |
TriSalus Life Sciences, Inc. (NASDAQ:TLSI ) Q2 2024 Earnings Call Transcript August 15, 2024 9:00 AM ET Company Participants Jim Young - SVP, IR and Treasurer Mary Szela - President and CEO Alex Kim - SVP, Interventional Radiology Steven Katz - CMO Sean Murphy - CFO Conference Call Participants Justin Walsh - JonesTrading Operator Good morning, and welcome to TriSalus Science Second Quarter 2024 Earnings Conference Call. Currently, all participants are on listen-only mode. |
seekingalpha.com |
2024-08-15 18:33:07 |
Czytaj oryginał (ang.) |
| TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants |
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today the expiration and results of its previously announced exchange offer (the “Offer”) and consent solicitation (the “Consent Solicitation”) relating to its warrants (the “Warrants”) identified in the Prospectus/Offer to Ex. |
businesswire.com |
2024-06-26 21:45:00 |
Czytaj oryginał (ang.) |
| TriSalus Life Sciences: Falling Despite Moving Forward Into The Market |
TriSalus Life Sciences, Inc. is focusing on developing organ-targeted therapy delivery mechanisms and pairing them with their own drugs. Nelitolimod, a TLR9 activator, is showing promising results in various solid tumor contexts, including liver and pancreatic cancers. Despite financial concerns, TriSalus Life Sciences' growing sales and promising clinical data make them a potential bargain investment when considered for the longer term. |
seekingalpha.com |
2024-06-25 19:17:24 |
Czytaj oryginał (ang.) |
| TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting |
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI), an oncology company integrating its novel Pressure Enabled Drug Delivery™ (PEDD™) technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced that data from its Phase 1b PERIO-02 clinical trial was presented in a poster session at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, taking place May 31-June 4, 2024, in Chicago, Illinois. The PEDD approac. |
businesswire.com |
2024-06-03 11:00:00 |
Czytaj oryginał (ang.) |
| TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants |
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today that it has commenced an exchange offer (the “Offer”) and consent solicitation (the “Consent Solicitation”) relating to its warrants (the “Warrants”) identified in the Prospectus/Offer to Exchange (as defined below). The purpose of. |
businesswire.com |
2024-05-24 10:05:00 |
Czytaj oryginał (ang.) |
| TriSalus Life Sciences, Inc. (TLSI) Q1 2024 Earnings Call Transcript |
TriSalus Life Sciences, Inc. (NASDAQ:TLSI ) Q1 2024 Earnings Conference Call May 15, 2024 9:00 AM ET Company Participants Jim Young – Senior Vice President-Investor Relations and Treasurer Mary Szela – President and Chief Executive Officer Sean Murphy – Chief Financial Officer Conference Call Participants Justin Walsh – JonesTrading Operator Good morning. And welcome to TriSalus Life Sciences First Quarter 2024 Earnings Conference Call. |
seekingalpha.com |
2024-05-15 15:40:31 |
Czytaj oryginał (ang.) |
| TriSalus Reports Q1 2024 Financial Results and Business Update |
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences Inc., (Nasdaq: TLSI), today announced its financial results for the first quarter ended March 31, 2024, and provided a business update. “I'm proud to highlight our strong start in the first quarter of 2024 with 116% growth in revenues compared to the first quarter of 2023 and significantly improving our financial position with our debt financing facility with OrbiMed,” said Mary Szela, Chief Executive Officer of TriSalus. “With our recent positive. |
businesswire.com |
2024-05-15 12:00:00 |
Czytaj oryginał (ang.) |
| TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors |
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today the appointment of Liselotte Hyveled to its Board of Directors. Ms. Hyveled brings over two decades of experience stimulating scientific innovation and advancing pharmaceutical pipelines through research and development excellence. “We are thrilled to welcome Li. |
businesswire.com |
2024-05-07 11:00:00 |
Czytaj oryginał (ang.) |
| TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call |
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today it will host a conference call and webcast on May 15, 2024, at 9:00 a.m. ET to discuss financial results for the first quarter ended March 31, 2024, and provide a business update. A press release detailing the first quarter results will be issued prior to the c. |
businesswire.com |
2024-05-06 20:58:00 |
Czytaj oryginał (ang.) |
| TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives |
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences Inc., (Nasdaq: TLSI), today announced the closing of a debt financing facility for up to $50 million with OrbiMed, a healthcare investment firm. The capital is expected to provide financial flexibility to support the execution of strategic expansion plans and fuel continued growth. Under the terms of the Credit Agreement (the “Credit Agreement”) with OrbiMed, the Company borrowed $25 million at closing. In addition, an aggregate of up to an additi. |
businesswire.com |
2024-04-30 20:35:00 |
Czytaj oryginał (ang.) |
| TriSalus Life Sciences, Inc. (TLSI) Q4 2023 Earnings Call Transcript |
TriSalus Life Sciences, Inc. (TLSI) Q4 2023 Earnings Call Transcript |
seekingalpha.com |
2024-04-01 14:56:02 |
Czytaj oryginał (ang.) |
| TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting |
DENVER & SALT LAKE CITY--(BUSINESS WIRE)--Technology from TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, was featured in two oral presentations at the Society of Interventional Radiology Annual Scientific Meeting. PERIO-03 Phase 1/1b Update TriSalus is studying an investigational class C toll-like receptor-9 (TLR9) agonist, nelitolimod (formerly SD. |
businesswire.com |
2024-03-26 10:00:00 |
Czytaj oryginał (ang.) |
| TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting |
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today that the Company will present data from recent research findings at the 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting, to be held March 23-28, 2024, in Salt Lake City, Utah. TriSalus will share data on the technical feasibility and saf. |
businesswire.com |
2024-03-21 10:00:00 |
Czytaj oryginał (ang.) |
| TriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial Results |
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) announced today that the Company will host a conference call and webcast on April 1, 2024, at 9:00 a.m. ET to discuss financial results for the fourth quarter and full year ended December 31, 2023, and provide a business update. A press release detailing the fourth quarter and full year results will be issued prior to the call. Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial Results Full financial results fo. |
businesswire.com |
2024-03-11 19:15:00 |
Czytaj oryginał (ang.) |